XK
ALLO icon

Xact Kapitalforvaltning’s Allogene Therapeutics ALLO Stock Holding History

Xact Kapitalforvaltning’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$227K Hold
11,700
– – ﹤0.01% 1152
2019
Q4 		$304K Buy
+11,700
New +$322K 0.01% 1236

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Xact Kapitalforvaltning's ALLO Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Allogene Therapeutics (ALLO) position steady in Q1 2020 at 11,700 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

Xact Kapitalforvaltning first reported a position in ALLO in Q4 2019 and has held it in 2 quarters since. The position peaked at $304K in Q4 2019. 115 funds tracked by Wall St. Rank hold ALLO as of Q1 2020.

  • Xact Kapitalforvaltning held 11,700 shares of Allogene Therapeutics worth $227K as of Q1 2020.
  • Xact Kapitalforvaltning left its Allogene Therapeutics share count unchanged in Q1 2020.
  • Allogene Therapeutics made up ﹤0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #1152 holding.
  • Xact Kapitalforvaltning first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 2 quarters since.
  • Xact Kapitalforvaltning's Allogene Therapeutics position peaked at $304K in Q4 2019.
  • 115 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.